markets.businessinsider.com
Microbiotica unveils data on the mechanism of action of MB310, a clinical-stage drug candidate in development for the treatment of ulcerative colitis
Patients and clinicians following new, non‑immunosuppressive approaches to UC may be interested because MB310 is an oral live‑biotherapeutic designed to induce remission and is entering clinical testing.
The work focuses on biological mechanisms relevant to UC (barrier healing, cytokine balance, regulatory T‑cells) that could inform future treatments if clinical trials are positive.
Adult patients with ulcerative colitis, clinicians treating IBD, researchers in microbiome therapeutics and drug development, and people interested in novel non‑immunosuppressive IBD therapies.
What To Know
Microbiotica presented preclinical data on MB310, an oral live biotherapeutic product (a defined eight‑strain bacterial consortium) being developed for ulcerative colitis.
The company reported multiple proposed mechanisms of action from preclinical studies—enhancing epithelial barrier healing, modulating cytokine balance (TNF and IL‑10), and inducing regulatory T‑cells—and noted MB310 is in a Phase 1 randomized, placebo‑controlled COMPOSER‑1 trial with data expected by end of 2025.
This is a company press release summarizing preclinical mechanistic data and ongoing early clinical testing of an investigational microbiome-derived therapy for UC. The findings reported are mechanistic and preclinical; the product is currently in a Phase 1 study assessing safety, tolerability, engraftment, and early signals of efficacy.
No clinical efficacy results from human participants are reported in this article. The COMPOSER‑1 trial is enrolling patients with active, mild‑to‑moderate UC and will measure engraftment of the bacterial strains as well as clinical outcomes; a readout is expected by the end of 2025.
The article links to posters presented at scientific meetings for more technical detail. If you want the original source materials, the press release and linked conference posters are referenced by Microbiotica and were presented at Keystone Symposia and ECCO.
This article is a company press release reporting preclinical mechanistic data and announcing an ongoing Phase 1 trial; it does not present peer‑reviewed clinical results. Early mechanistic and preclinical findings do not guarantee clinical benefit.
The Phase 1 COMPOSER‑1 trial is designed primarily to assess safety, tolerability, and engraftment; efficacy conclusions must wait for randomized human data. The linked conference posters may provide additional technical details.
